Physician profile

Nkechi Mba

Pediatric Hematology-Oncology · Corpus Christi, TX

NPI 1477501856

$333.66

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Pediatric Hematology-Oncology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$69.89
Education$30.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Servier Pharmaceuticals LLC $123.28 2020-2022
Genentech USA, INC. $88.00 2019
Seagen INC. $45.41 2023 Adcetris
Alexion Pharmaceuticals, INC. $30.00 2024 Ultomiris
Novartis Pharmaceuticals Corporation $24.48 2023
Rare Disease Therapeutics, INC. $22.49 2019

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Nkechi Mba

$333.66

in general payments reported 2019-2025

Years
2019-2024
Top company
Servier Pharmaceuticals LLC

https://glasscript.com/doctor/1145761/nkechi-mba

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.